Patents by Inventor Cecilia M. Bastos

Cecilia M. Bastos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Proteasome activity enhancing compounds
    Patent number: 11958873
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: April 16, 2024
    Assignee: Kineta, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20240109922
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: December 4, 2023
    Publication date: April 4, 2024
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230242557
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: August 3, 2023
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20230183256
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: November 18, 2022
    Publication date: June 15, 2023
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • Proteasome activity enhancing compounds
    Patent number: 11560385
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 24, 2023
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20220298181
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 17, 2021
    Publication date: September 22, 2022
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20220227739
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: August 25, 2021
    Publication date: July 21, 2022
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • METHODS OF TREATING PULMONARY DISEASES AND DISORDERS
    Publication number: 20220175735
    Abstract: The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.
    Type: Application
    Filed: June 22, 2021
    Publication date: June 9, 2022
    Inventors: John Miller, Cecilia M. Bastos, Benito Munoz
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 11248010
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: February 15, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Proteasome activity enhancing compounds
    Patent number: 11242361
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: February 8, 2022
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20210369749
    Abstract: The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.
    Type: Application
    Filed: October 5, 2018
    Publication date: December 2, 2021
    Inventors: Daniel Parks, Benito Munoz, Cecilia M. Bastos
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 11136313
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: October 5, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 11098035
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 24, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods of increasing CFTR activity
    Patent number: 11083709
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 10, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20210115057
    Abstract: The present invention is directed to compounds having the Formulae (Ia), (Ib), (Ic), or (Id); or the Formulae (II), (IIa), (IIb), or (IIc); or the Formulae (III), (IIIa), (IIIb), (IIIc), (IIId), or (IIIe), and pharmaceutically acceptable salts, solvates, clathrates and prodrugs of any Formula thereof, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Inventors: Matthew Cullen, Cecilia M. Bastos, Daniel Parks, Benito Munoz
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20210061823
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: April 14, 2020
    Publication date: March 4, 2021
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10899751
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 26, 2021
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20200385365
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: December 17, 2019
    Publication date: December 10, 2020
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY
    Publication number: 20200360348
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Application
    Filed: December 11, 2019
    Publication date: November 19, 2020
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20200308198
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait